Tacrolimus exhibits inter-patient pharmacokinetic variability attributed to CYP3A5 isoenzymes and the efflux transporter, P-glycoprotein. Most black renal transplant recipients require higher tacrolimus doses compared to whites to achieve similar troughs when race-adjusted recommendations are used. An established guideline provides tacrolimus genotype dosing recommendations based on CYP3A5*1(W/T) and loss of protein function variants: CYP3A5*3 (rs776746), CYP3A5*6 (rs10264272), CYP3A5*7 (rs41303343) and may provide more comprehensive race-adjusted dosing recommendations. Our objective was to develop a tacrolimus population pharmacokinetic model evaluating demographic, clinical, and genomic factors in stable black and white renal transplant recipients. A secondary objective investigated race-based tacrolimus regimens and genotype-specific dosing. Sixty-seven recipients receiving oral tacrolimus and mycophenolic acid ࣙ6 months completed a 12-hour pharmacokinetic study. CYP3A5*3, *6, *7 and ABCB1 1236C>T, 2677G>T/A, 3435C>T polymorphisms were characterized. Patients were classified as extensive, intermediate, and poor metabolizers using a novel CYP3A5*3*6*7 metabolic composite. Modeling and simulation was performed with computer software (NONMEM 7.3, ICON Development Solutions; Ellicott City, Maryland). A 2-compartment model with first-order elimination and absorption with lag time best described the data. The CYP3A5*3*6*7 metabolic composite was significantly associated with tacrolimus clearance (P value < .05), which was faster in extensive (mean: 45.0 L/hr) and intermediate (29.5 L/hr) metabolizers than poor metabolizers (19.8 L/hr).Simulations support CYP3A5*3*6*7 genotype-based tacrolimus dosing to enhance general race-adjusted regimens, with dose increases of 1.5-fold and 2-fold, respectively, in intermediate and extensive metabolizers for comparable exposures to poor metabolizers. This model offers a novel approach to determine tacrolimus dosing adjustments that maintain comparable therapeutic exposure between black and white recipients with different CYP3A5 genotypes.
Tacrolimus is a calcineurin inhibitor immunosuppressant, which is widely prescribed with mycophenolic acid (MPA), corticosteroids, or alternate immunosuppressant agents (eg, azathioprine) to prevent allograft rejection in solid-organ transplant recipients. 1, 2 Tacrolimus exhibits a narrow therapeutic index, with troughs ranging from 4 to 15 ng/mL for renal transplant recipients based upon prescribing full or calcineurin inhibitor minimization protocols. [3] [4] [5] [6] [7] [8] Considerable inter-and intra-patient variability in tacrolimus pharmacokinetics exists that can be attributed to race, sex, clinical factors, and drug-drug interactions that impact allograft survival. [3] [4] [5] [6] Compared to whites, most black transplant recipients require larger tacrolimus doses to achieve therapeutic trough concentrations. [9] [10] [11] Therapeutic drug monitoring of trough concentrations is the standard of care to ensure patient treatment safety and allograft survival. 8 However, there exists a poor correlation between tacrolimus dosage and troughs, requiring additional research into factors influencing patient drug exposure.
bloodstream. 13 Tacrolimus is highly metabolized in the liver and small intestine primarily by cytochrome P450 (CYP) 3A5 enzymes. 6, 14, 15 It is also a substrate for the efflux transporter P-glycoprotein (P-gp). 3, 6, 9 Fifteen metabolites of tacrolimus can be formed and excreted through the biliary route, with less than 1% of the parent drug remaining unchanged. 16 Single nucleotide polymorphisms (SNPs) identified in the CYP3A5 and ABCB1 genes are associated with modulation of CYP3A5 enzyme and P-gp function, respectively, which contribute to the inter-patient variability in tacrolimus pharmacokinetics. 9, [17] [18] [19] Genetic variations in the CYP3A5 gene have explained 40% to 50% of the variability in tacrolimus clearance. 9 The variant CYP3A5*3 (rs776746) has been commonly associated with reduction in the functional CYP3A5 enzyme or loss of protein function and is detected primarily in whites. 20 In blacks, CYP3A5 variants including CYP3A5*6 (rs10264272) and CYP3A5*7 (rs41303343), are also associated with loss of protein function, and may contribute to interracial variability in tacrolimus pharmacokinetics. 20, 21 The Clinical Pharmacogenetics Implementation Consortium (CPIC) has assigned CYP3A5 phenotypes based on *allele diplotypes. 22 Patients are identified as extensive metabolizers (*1/*1), intermediate metabolizers (*1/*3, *1/*6, *1/*7), or poor metabolizers (*3/*3, *6/*6, *7/*7, *3/*6, *3/*7, *6/*7). Based on these phenotypes, CPIC has provided CYP3A5 genotype based tacrolimus dosing guidelines to help achieve target trough concentrations for solidorgan transplants in adults and children. For CYP3A5 poor metabolizers, therapy should be initiated with the standard recommended dose, whereas for CYP3A5*1 expressers, which include intermediate and extensive metabolizers, a suggested regimen should be increased to 1.5-2 times the standard dose without exceeding 0.3 mg/kg/day. 22 The Food and Drug Administration (FDA) initial dosing recommendations for oral tacrolimus are based on the type of organ transplant, race, and time posttransplant, which is 0.1 mg/kg/day, administered at 0.05 mg/kg every 12 hours, for adult kidney transplant recipients in combination with mycophenolic acid. 23 However, higher tacrolimus dosing regimens are recommended for black patients compared to whites based on the time post-transplant. These recommendations are supported by several reports comparing clinical troughs and bioavailability between black and white healthy subjects and renal transplant recipients. 24, 25 Over the past 2 decades, more than 50 population analyses have been conducted to investigate tacrolimus pharmacokinetics and identify significant covariates explaining inter-patient variability to better guide clinicians in defining an optimal dosing regimen. 26 Factors commonly reported to influence tacrolimus pharmacokinetics include total body weight (TBW), hematocrit, time post-transplant, hepatic function, and CYP3A5*3 polymorphisms. 26 In addition, approximately 50% of population-based pharmacokinetic analyses were performed using tacrolimus trough concentrations with limited inclusion of critical patient covariates. 26 To our knowledge, no population analysis has been conducted comparing white and black recipients.
The primary objectives of this study are to (1) develop a population pharmacokinetic model using intensively sampled tacrolimus profiles in stable black and white renal transplant patients receiving tacrolimus minimization dosing with MPA, and (2) explore the effects of major demographic, clinical, and targeted genomic covariates on tacrolimus pharmacokinetic parameters. Using the final pharmacokinetic model, the secondary objective evaluates the CPIC and FDA tacrolimus dosing recommendations incorporating CYP3A5*3*6*7 genotypes and race.
Methods

Ethical Approval and Study Design
The study protocol was approved by the University at Buffalo Health Sciences Institutional Review Board before enrollment (IRB# PHP0599703-4). The clinical trial was conducted in accordance with the Declaration of Helsinki, and is consistent with the Principles of the Declaration of Istanbul as outlined in the "Declaration of Istanbul on Organ Trafficking and Transplant Tourism." Written informed consent was obtained from all individual patients included in the study.
Sixty-seven stable renal transplant recipients (35 blacks and 32 whites) receiving maintenance oral tacrolimus (Prograf R ) and MPA as entericcoated mycophenolate sodium (ECMPS; Myfortic R ) for ࣙ6 months were included in a cross-sectional, open-label, 12-hour pharmacokinetic study. The study was conducted at the University at Buffalo Research Center at the Erie County Medical Center from February 2010 until June 2011. Clinical stability was based on physical examination, comprehensive metabolic panel, fasting lipid panel, and complete blood count at enrollment and on the study morning. Tacrolimus doses were administered twice daily and adjusted to 4 to 9 ng/mL trough concentrations using a minimization dosing protocol, time post-transplant, and clinical response. ECMPS dose was adjusted based upon clinical response. Medication adherence was verified at enrollment as well as 1 week and 48 hours prior to the study by research personnel with medication diaries provided by patients. Ethnicity for 2 previous generations was verified. The inclusion criteria were (1) ࣙ 6 months post-renal transplant; (2) age 25-70 years; (3) first-or second-time deceaseddonor or living allograft recipient; (4) stabilized on same dose of immunosuppressive drugs for ࣙ7 days prior to study; (5) serum creatinine ࣘ3.25 mg/dL with no change in serum creatinine >0.25 mg/dL during prior 2 visits; and (6) leukocyte count ࣙ3000/mm 3 and hemoglobin ࣙ8.0 g/dL. Exclusion criteria were (1) infection within 2 weeks; (2) acute rejection within 2 weeks; (3) concomitant drugs interfering with tacrolimus or MPA absorption; (4) concomitant cytochrome P450 3A4/3A5 or P-gp inhibitors or inducers within 4 weeks; and (5) significant cardiovascular, gastrointestinal, hematologic, psychiatric, neurologic, or oncologic, diseases that would limit participation.
Patients were studied at steady-state concentrations of tacrolimus and ECMPS, with the receipt of the same dose for ࣙ7 days prior to study. Patients took immunosuppressives between 5:30 and 6:30 PM followed by a 12 hour fast prior to study. Patients were admitted at 6:00 AM, vital signs were documented, and an intravenous angiocatheter inserted. A 0-hour blood sample (ß15 mL) was collected prior to immunosuppressive administration for drug troughs and fasting laboratory tests. Study medications were administered orally from a single lot of tacrolimus and ECMPS by 7:00 AM. Patients remained upright throughout the study. Standardized low-fat meals were provided after 4 hours. Anti-hypertensive drugs were administered after 1.5 hours, with insulin, anti-lipidemic, and other medications administered 4 hours after the immunosuppressives. Blood samples (ß7 mL) were collected at 0 (pre-dose), 1, 2, 3, 4, 6, 8, 10, and 12 hours post-dose. Whole blood samples were aliquoted immediately and stored at −70°C until analysis.
An additional 20 mL of blood was collected in Cell Preparation Tubes (CPT R , BD Vacutainer) pre-dose with separation of peripheral blood mononuclear cells, which were harvested, immediately frozen in liquid nitrogen, and stored at −70°C until genotype analysis.
Bioanalytics
Blood tacrolimus concentrations were measured using a chemiluminescent microparticle immunoassay system (ARCHITECT, Abbott, Abbott Park, Illinois). Assay validation was completed with a calibration standard curve ranging from 1 to 30 ng/mL with 0.5 ng/mL as the lower limit of detection. Three quality controls were prepared at 3.0, 12.0, and 25.0 ng/mL (Bio-Rad; Hercules, California) and were co-analyzed with all samples and standards. The interday coefficient of variation for each QC was < 4%, and intra-day coefficient of variation was <5%. Selected trough and peak concentrations (N = 40 samples) were analyzed using a validated LC/MS/MS assay by an external analytical laboratory and compared to the results generated from the ARCHITECT tacrolimus assay with excellent agreement (R 2 = 0.98). For tacrolimus LC/MS/MS assay, the inter-day and intra-day coefficient of variation were < 5% at the low and high concentration quality control.
Genotyping Assays
All patient samples were viable and analyzed in a genomics laboratory (University of New England Genomics, Analytics, and Proteomics Core). Laboratory personnel performing the genotyping analysis were blinded to patient treatment. Genomic DNA was isolated from peripheral blood mononuclear cells using the Wizard R Genomic DNA Purification system (Promega, Madison, Wisconsin) following manufacturer instructions. A total of 10 ng of genomic DNA was used in genotyping reactions for the following SNPs: ABCB1:
and CYP3A5*3 (rs776746), CYP3A5*6 (rs10264272), and CYP3A5*7 (rs41303343) using allelic discrimination assays (TaqMan, Applied Biosystems, Foster City, California) with the CFX96 Real-Time Polymerase Chain Reaction Detection System (Bio-Rad, Raleigh, North Carolina). Each SNP was analyzed in duplicate experiments. Allele frequencies were confirmed in Hardy-Weinberg equilibrium when adjusted for race.
CYP3A5*3*6*7 Metabolic Composite CYP3A5 exhibits significant allelic heterogeneity. Three SNPs CYP3A5*3, CYP3A5*6 and CYP3A5*7 result in loss of protein gene expression. Loss of function by any of these SNPs can occur independent of allelic status at the other two loci. A CYP3A5*3*6*7 metabolic composite based on the combined allelic status for each loss of function SNP was used to characterize each patient as extensive (cEM CYP3A5 ), intermediate (cIM CYP3A5 ) or poor metabolizers (cPM CYP3A5 ), as depicted in Figure 1 . This composite followed the tacrolimus dosing guidelines provided by CPIC with the exception of the double heterozygous condition, which is not addressed by CPIC. 22 Metabolic status using poor, intermediate and extensive metabolizer categories was also included for CYP3A5*1 and *3 genotypes only and are summarized in the Supporting Information.
Pharmacokinetic Modeling
Population pharmacokinetic modeling and simulation were performed using nonlinear mixed-effects modeling with computer software (NONMEM 7.3.0, ICON Development Solutions, Ellicott City, Maryland). The first-order conditional estimation with interaction method was used to estimate the parameters. Oneand 2-compartment models with first-order absorption were compared, defined by apparent pharmacokinetic parameters in the absence of intravenous data. The use of transit compartments and a lag-time for describing drug absorption were explored. Between-subject variability (BSV) was assumed to be log-normally distributed and tested by an exponential model on pharmacokinetic parameters. Additive, proportional, and mixed residual variability models were tested. Model selection was based upon the goodness-offit plots, precision of parameter estimates (relative standard error; RSE), and changes in the minimum objective function value. The R-based tool Xpose 4.5.3 and GraphPad Prism 6.04 (GraphPad Software Inc, La Jolla, California) were used for graphic presentations and statistical analysis.
Covariate Analysis
Covariate analysis was performed to explore the potential effects of patient characteristics on model parameters associated with BSV. All patient characteristics listed in Table 1 were investigated as potential covariates with the exception of study dose and patient number. No data were missing among patients. Individual SNPs for ABCB1 and CYP3A5*3 polymorphisms as well as the CYP3A5*3*6*7 metabolic composite were examined. Significant covariates were selected using a classical stepwise approach. 27 The influence of continuous covariates on the pharmacokinetic parameters was modeled according to a power model scaled to the population median covariate value. The influence of categorical covariates was modeled using a fractional change due to the covariate value. Model refinements (addition of BSV and correlations between BSV) were tested before and after the covariate analysis.
Model Evaluation
In addition to the standard goodness-of-fit plots, other methods were used to evaluate model performance. The precision of the final estimated pharmacokinetic parameters was evaluated using a nonparametric bootstrap resampling method. 28 One thousand replicates of the analysis data set were generated by bootstrap and run with the final model to obtain the median and 95th percentile of all parameter estimates, which were compared to those of the final model. To evaluate the model predictive performance while accounting for different administered doses among patients and identified covariates, internal validation was performed using a prediction-corrected visual predictive check. 29 One thousand replicates of the data set were simulated conditional on the final pharmacokinetic parameters. The observed data and their 5th, 50th, and 95th percentiles were overlaid on the 90th confidence interval of the 5th, 50th, and 95th percentiles of the simulations to visually assess model performance. All data were corrected using the median of the population prediction within the associated time bin. 
Dosing Adjustment Simulations Based Upon Published Guidelines
Using the final model, simulations (N = 1000) were conducted to explore the effect of significant covariates on tacrolimus exposure after oral administration of a standard dose of 0.075 mg/kg/day, given as 0.0375 mg/kg every 12 hours, which was selected as the most frequently administered standard tacrolimus dose based upon literature review. 26 Individual exposures were assessed by the area under the concentration curve (AUC) between 0 and 12 hours at steady state (AUC ss,0-12hr ):
with Dose and CL/F as the individual study dose and model-estimated apparent clearance.
To evaluate the CPIC tacrolimus dosing guidelines, simulations (N = 1000) were performed for cIM CYP3A5 and cEM CYP3A5 with new dose levels consisting of 1.5-and 2-fold change compared to cPM CYP3A5 . Tacrolimus exposure using simulated AUC ss,0-12hr and 12 hour trough concentrations were compared across all CYP3A5*3*6*7 metabolic composite and dose-level groups. They were also compared to the suggested therapeutic ranges for tacrolimus AUC of 120 to 200 ng·h/mL and trough concentrations of 4-12 ng/mL targeted for kidney transplant recipients greater than 6 months post-transplant using a tacrolimus minimization protocol. These ranges were selected based upon the tacrolimus minimization protocol used by the UB Transplant Center and literature review. 4, 7, [30] [31] [32] This analysis was also completed for CYP3A5*1 and *3 phenotypic groups.
Model simulations were also conducted based on the results reported in the FDA-approved monograph for blacks and whites for different time post-transplant. 23 Tacrolimus exposure (AUC ss,0-12hr ) and trough concentrations were generated using individual pharmacokinetic parameters estimated from the model after administration of 0.13 mg/kg/day for whites and 0.19 mg/kg/day for black (ie, 0.065 and 0.095 mg/kg every 12 hours). Both were compared to the targeted therapeutic ranges. 20 This analysis was also completed for CYP3A5*1 and *3 phenotypic groups.
Results
Data Summary and Patient Characteristics
A total of 594 tacrolimus steady-state concentrations from 67 patients were available for population pharmacokinetic analysis. The study cohort included 38 men and 29 women, 48% whites, and 52% blacks, with a median age of 46 years, and a median total body weight (TBW) of 85.9 kg. All concentrations were above the limit of quantification for the assay. Dose-normalized concentration-time profiles exhibited a large degree of variability within the CYP3A5*3*6*7 Figure 2 . Observed tacrolimus dose-normalized concentrations (ng/mL) compared to time after drug administration stratified by CYP3A5*3*6*7 metabolic composite. For each patient, tacrolimus concentrations were divided by the recipient's dose and multiplied by the mean study dose for the population, which was 3.4 mg. The red, green, and blue dots represent individual tacrolimus concentrations for CYP3A5 extensive (cEM CYP3A5 ), intermediate (cIM CYP3A5 ), and poor metabolizers (cPM CYP3A5 ).
metabolic composite groups (Figure 2) . The distribution of the CYP3A5*3*6*7 metabolic composite groups was highly correlated with race, with 91% of whites identified as cPM CYP3A5 and 83% of blacks identified as cIM CYP3A5 or cEM CYP3A5 . Patient characteristics were grouped according to CYP3A5*3*6*7 metabolic composites and summarized in Table 1 . The Supporting Information (Section II) summarizes patient demographics and clinical characteristics in Table  S3 stratified by CYP3A5*1 and *3 genotype groups.
Population Pharmacokinetic Modeling
A two-compartment model with first-order absorption and elimination and an absorption lag time best described tacrolimus pharmacokinetics. BSV was included on the absorption rate constant (k a ), central clearance and volume of distribution (CL/F, V/F), and intercompartmental clearance (CL p /F). The associated shrinkages were small (<20%) and supported an unbiased covariate inclusion. A proportional error model best described residual variability. Visual inspection of individual pharmacokinetic parameter estimates vs covariates showed potential trends for CYP3A5*3*6*7 metabolic composite, race, black women, and ABCB1-2677 polymorphisms on CL/F, serum creatinine on CL p /F, TBW and ABCB1-3435 polymorphisms on V/F, and presence of diabetes on k a . CYP3A5*3*6*7 metabolic composite exhibited the strongest effect on CL/F (Figure 3 ). In the forward building step, inclusion of CYP3A5*3*6*7 metabolic composite on CL/F, TBW on V/F, and diabetes on k a produced a significant decrease in objective function value (>3.84, P < .05). After backward elimination, only CYP3A5*3*6*7 metabolic composite and TBW were retained as significant covariates (P < .01), resulting in a total decrease in the objective function value by 33.6 points (Table S1 ). Individual CL/F i and V/F i values were predicted from the final model by the following equations:
in which H1 = 1 for cIM CYP3A5 and H2 = 1 for cEM CYP3A5 (0 otherwise), and η i terms are the estimated BSV on CL/F and V/F. Typical values of CL/F for cPM CYP3A5 , cIM CYP3A5 and cEM CYP3A5 were 19.7, 28.6, and 44.3 L/hr 1 . Inclusion of covariates on CL/F and V/F reduced the magnitude of BSV from 46.6 to 37% (CL/F) and from 83.2 to 76.7% (V/F). No correlation between random effects was significant. All final pharmacokinetic parameters were well estimated (relative standard error <30%) and are summarized in Table 2 . The supplemental data summarized in Tables S5 and S4 reflect the model using CYP3A5 *1 and *3 genotype groups only. Although there is a slight bias for the population-level fit (Fig. S1a) , the goodness-of-fit plots (ie, observed concentrations vs population and individual predictions, conditional weighted residuals vs population 
) where H1 = 1 for CYP3A5 intermediate metabolizers (cIM CYP3A5 ) and H2 = 1 for CYP3A5 extensive metabolizers (cEM CYP3A5 ). TBW, total body weight (kg).
predictions and time) did not show significant misspecification or bias in the final model ( Figure S1a-d) . Results of the nonparametric bootstrap are listed in Table 2 . Mean values for all parameters were within 5% of those obtained from the final model. The 95%CI was relatively narrow and did not include the value zero, suggesting reliable model-parameter estimates. The prediction-corrected visual predictive checks for all patients and stratified by CYP3A5*3*6*7 metabolic composite showed that the central tendency and variability of tacrolimus concentrations in the study population were well predicted by the final model (Figure 4 ).
Dosing Adjustment Simulations Using Published Guidelines
After administration of a common clinical dose of 0.075 mg/kg/day of tacrolimus, administered as 0.0375 mg/kg every 12 hours, model simulations showed differences in steady-state concentration-time profiles across CYP3A5*3*6*7 metabolic groups ( Figure 5 ), suggesting a need for dosing adjustment. cPM CYP3A5 exhibited higher tacrolimus exposure (mean AUC ss,0-12hr 170 ng·h/mL) and trough concentrations (mean 10.9 ng/mL) than cIM CYP3A5 (AUC ss,0-12hr 116 ng· h/mL and trough 6.70 ng/mL) and EM CYP3A5 (AUC ss,0-12hr 80.8 ng·h/mL and trough 4.05 ng/mL).
Comparison with model-simulated tacrolimus exposures and troughs following 1.5-and 2-fold increase in doses for cIM CYP3A5 and cEM CYP3A5 are shown in Figures 6A and B. With the 0.075 mg/kg/day dosing regimen (0.0375 mg/kg every 12 hours), 47% of cPM CYP3A5 exhibited AUC ss,0-12hr within the therapeutic range, whereas the majority of cIM CYP3A5 and cEM CYP3A5 showed underexposure of 62% and 88%, respectively. In 40% of the cIM CYP3A5 recipients using a 1.5-fold increased dose, similar tacrolimus exposures to cPM CYP3A5 were predicted, but a higher risk of overexposure was determined in 52% of this group with a 2-fold higher dose. In 44% of cEM CYP3A5 recipients, a 2-fold higher dose predicted similar exposure to cPM CYP3A5 .
Model-simulated exposures and trough concentrations for blacks in this study receiving a tacrolimus dose of 0.19 mg/kg/day (0.095 mg/kg every 12 hours) as recommended in the FDA monograph are shown in Figures 7A and B . Most blacks classified as cEM CYP3A5 had tacrolimus exposures within the therapeutic range, while 81% and 100% of blacks classified as cIM CYP3A5 and cPM CYP3A5 exhibited overexposure. Simulations for whites receiving a tacrolimus dose of 0.13 mg/kg/day resulted in overexposure for most patients (data not shown). For all simulations, similar conclusions were observed considering troughs.
The Supporting Information summarizes the dosing adjustment simulations performed for CYP3A5*1 and *3 genotype groups in Figures S4-S8 .
Discussion
This population-based pharmacokinetics model identifies a significant impact of multiple CYP3A5 genotypes on tacrolimus clearance using the novel CYP3A5*3*6*7 metabolic composite. Notable differences were found in tacrolimus pharmacokinetics in patients identified as cPM CYP3A5 , cIM CYP3A5 and cEM CYP3A5 , and reinforces the need for well-defined dosing adjustments to achieve targeted troughs and AUC ss,0-12hr . The pharmacokinetic analysis resulted in a 2-compartment model with delayed absorption and first-order elimination to describe the full concentration-time profiles. This model is consistent with other pharmacokinetic models using intensive sampling. 26 Our final pharmacokinetic parameters and associated BSV are in agreement with previous estimates for tacrolimus. 26 Most tacrolimus population pharmacokinetic models using only trough concentrations resulted in 1-compartment models and results in predictive limitations. [33] [34] [35] [36] The effect of TBW was included on V/F with an allometric coefficient of 1 as previously reported. 35, [37] [38] [39] Time post-transplant and hematocrit had no impact in our tacrolimus pharmacokinetic model in spite of significance found in previous models. 26 This finding is likely due to the narrow inclusion criteria range for hemoglobin and hematocrit and the clinical stability of these patients. 26 The distribution of CYP3A5 genotypes differs by race, which may explain differences in tacrolimus pharmacokinetics between whites and blacks who require higher tacrolimus doses to achieve comparable concentrations. 9, 10, 40 In our covariate analysis, the impact of race on tacrolimus clearance was significant until the inclusion of the CYP3A5*3*6*7 metabolic composite and a high correlation was found between these 2 covariates. White patients were primarily poor metabolizers (cPM CYP3A5 ), with none categorized as cEM CYP3A5. Blacks were mainly intermediate (cIM CYP3A5 ) and extensive (cEM CYP3A5 ) metabolizers. These findings are consistent with the incidence for the loss of function CYP3A5*3 variant of greater than 90% that is reported in whites and an approximate frequency of 30% found in blacks. 41 However, it is important to consider the other variant alleles CYP3A5*6 and CYP3A5*7 that also result in a loss of function of the respective enzymes. The CYP3A5*6 and CYP3A5*7 polymorphisms are rare in whites, but exhibit higher frequencies in blacks of approximately 10%. Therefore, these variants contribute to the increased probability of non-functional enzymes, resulting in poor metabolic phenotypes in blacks and have important clinical implications. 41 The different racial distributions of the CYP3A5 variants support the use of the CYP3A5*3*6*7 metabolic composite for more comprehensive investigation of tacrolimus dosing adjustments.
The CYP3A5*3*6*7 metabolic composite was the most significant covariate explaining tacrolimus pharmacokinetic variability in our model. Significant differences in CL/F were found relative to the 3 phenotypes, with an approximate 1.5-fold and 2-fold increase for cIM CYP3A5 and cEM CYP3A5 compared to cPM CYP3A5 . The impact of the loss of function variants CYP3A5*3, *6 and *7 on tacrolimus pharmacokinetics has been reported in 2 studies investigating only black kidney transplant recipients using only trough concentrations.
10,21 Numerous tacrolimus population-based pharmacokinetic analyses were performed to explore the impact of the CYP3A5*3 genotypic variant alone, without consideration of CYP3A5*6 and *7 genotypes with limited inter-racial comparisons. 26 Therefore, to assess the superiority of the CYP3A5*3*6*7 metabolic composite compared to CYP3A5*3 variant only, as a source of tacrolimus pharmacokinetic inter-individual variability, we performed the same pharmacokinetic analysis considering CYP3A5*1 and *3 genotypes (see Supporting Information, section II). Significant differences on tacrolimus clearance were found among the 3 CYP3A5*3 genotypic groups: poor metabolizers (*3/*3), intermediate metabolizers (*1/*3) and extensive metabolizers (*1/*1) ( Figure S3 ). Tacrolimus clearance estimates for the CYP3A5*3 variant status were similar to those of the CYP3A5*3*6*7 metabolic composite (Table S4) . However, the inclusion of the metabolic composite explained more inter-individual variability for tacrolimus clearance. In addition, using the metabolic composite provided a comprehensive identification of patients with the loss-of-function variants since the presence of CYP3A5*6 and *7 are often missed in blacks who may be categorized as intermediate or extensive metabolizers when the CYP3A5*3 variant is only analyzed. 42 Unlike our analysis, the majority of the studies exploring the CYP3A5*3 variant show differences in tacrolimus clearance between CYP3A5 non-expressers (*3/*3) or poor metabolizers in comparison to CYP3A5*1 expressers, which combine both intermediate (*1/*3) and extensive (*1/*1) metabolizers. These findings may be explained by the limited incidence of *1/*1 variant Figure 6 . Boxplots of model-simulated tacrolimus AUC ss,0-12hr (A) and 12-hour trough concentrations (B) stratified by CYP3A5*3*6*7 metabolic composite, obtained with different dosing regimens (ie, Dose i = 0.075 mg/kg/day given as 0.0375 mg/kg every 12 hours, dose i × 1.5, and × 2). 20 The dashed lines represent the targeted therapeutic ranges: between 120 and 200 ng·h/mL for AUC ss,0-12hr , and between 5 and 12 ng/mL for 12 hour trough concentrations. 28 Percentages of patients exhibited AUC ss,0-12hr and trough concentrations above, within, and below the therapeutic range are indicated in each graph.
in other study populations that primarily enrolled white patients. 37, [43] [44] [45] [46] In these analyses, CYP3A5*1 expressers exhibited a 1.2-to 2.3-fold increase in tacrolimus clearance compared to CYP3A5 non-expressers. 26 Significant differences among the 3 CYP3A5*3 genotype groups were found in 2 studies involving Korean adult 35 and Mexican pediatric renal transplant patients. 47 When combining these results with the black recipients 10 , these analyses reported a 1.5-to 2-fold faster tacrolimus clearance in intermediate and extensive metabolizers using tacrolimus trough concentrations only. 10, 35, 47 Our results had a similar trend from the model developed using intensive sampling to generate a more accurate tacrolimus clearance.
Simulations were conducted with the final pharmacokinetic model to explore the impact of the Figure 7 . Individual model-simulated tacrolimus AUC ss,0-12hr (A) and 12-hour trough concentrations (B) stratified by CYP3A5*3*6*7 metabolic composite for the black patients receiving a dosing regimen of 0.19 mg/kg/day (0.095 mg/kg every 12 hours). 21 The dashed lines represent the targeted therapeutic ranges:between 120 and 200 ng·h/mL for AUC ss,0-12hr , and between 5 and 12 ng/mL for 12 hour trough concentrations. 28 Percentages of patients exhibited AUC ss,0-12hr and trough concentrations above, within, and below the therapeutic range are indicated in each graph.
CYP3A5*3*6*7 metabolic composite on tacrolimus steady-state exposure and trough concentrations (Figures 5 and 6) . A standard dose of 0.075 mg/kg/day (0.0375 mg/kg every 12 hours) was selected for our simulations based on the studies reviewed by Brook et al. 26 For comparison, the mean tacrolimus dose used in our study was 0.082 mg/kg. The primary goal of these simulations was to evaluate the dose adjustments required to achieve similar exposures among cPM CYP3A5 , cIM CYP3A5 , and cEM CYP3A5 . Using the final model, simulations revealed that using an initial dose of 0.075 mg/kg/day (0.0375 mg/kg every 12 hours), about 50% of PM CYP3A5 would achieve steady-state exposures and troughs within the targeted therapeutic range (Figure 6 ). 30 However, based on this dosing regimen, 62% of cIM CYP3A5 and 88% of cEM CYP3A5 were at a risk for sub-therapeutic exposures, which may increase the risk of allograft rejection. The CPIC guidelines recommend a 1.5-to 2-fold increase in the standard tacrolimus dose for intermediate and extensive metabolizers to achieve target troughs. To further individualize the CPIC guidelines, our simulations suggest that well-defined dosing increases should be considered to include 1.5-fold for cIM CYP3A5 and 2-fold for cEM CYP3A5 using the standard dose ( Figure 6 ). For instance, a 2-fold increased dose for cIM CYP3A5 could result in a high proportion of patients exceeding the therapeutic range, with an increased risk for toxicities or overimmunosuppression as depicted in Figure 6 . Similar findings were obtained when performing the same simulations with the tacrolimus pharmacokinetic model based on the CYP3A5*1 and *3 variant (see Figures S6 and S7) .
The updated FDA prescribing information suggests race-adjusted tacrolimus dosing for black kidney recipients based on time post-transplant. 23 Using our final pharmacokinetic model, simulations in the black patients demonstrated that the FDArecommended tacrolimus dose regimen of 0.19 mg/kg daily at 12 months post-transplant could result in overexposure for all cPM CYP3A5 and 81% of cIM CYP3A5 . See Figure 7 . Similar results were also found with the same simulations performed with the pharmacokinetics model based on CYP3A5*3 variant alone ( Figure S8 ). Therefore, consideration of the pertinent CYP3A5 variants concurrent to race may optimize dosing strategy and subsequent regimen adjustments in the black population. Other genotype factors may explain tacrolimus inter-patient variability, such as CYP3A4 variants and P-gp, which modulate tacrolimus metabolism and cellular distribution. 48 The genotype CYP3A4*22 (rs35599367), associated with reduced enzymatic activity, has been combined with the CYP3A5*3 variant to define poor, intermediate, and extensive metabolizers to explain tacrolimus pharmacokinetic variability. 49, 50 These studies reported that well-defined doses for each metabolic group was required to achieve comparable tacrolimus exposure. In our model, P-gp may not have been adequately represented by using individual ABCB1 polymorphisms in the covariate analysis. Use of ABCB1 haplotypes may provide a more comprehensive investigation of this efflux transporter and the associated inter-patient pharmacokinetic variability of tacrolimus. 51 Although this study included a small number of patients with no validation group included, the model developed has several advantages. This study was designed using intensive serial sampling strategy in clinically stable patients, which provides more accurate estimates of tacrolimus pharmacokinetic parameters. All patients were enrolled based upon well-defined inclusion and exclusion criteria. In addition, medication adherence and steady-state dosing conditions were carefully confirmed prior to study periods. All patients provided documentation of race for 2 previous generations.
Conclusion
The population pharmacokinetics model developed for tacrolimus identified the significant contribution of the CYP3A5*3*6*7 metabolic composite to predict inter-patient variability between white and black renal transplant recipients. Differences between these groups can be explained by the racial differences in the distribution of CYP3A5*3*6*7 polymorphisms and metabolic enzyme activity. Well-defined dosing adjustments among the 3 metabolic phenotype groups comparing early to late post-transplant periods should be further investigated because extensive and intermediate metabolizers require higher doses than poor metabolizers. This model predicted tacrolimus exposures when applied to race-specific FDA dosing guidelines and CPIC recommendations. This model also predicted troughs and AUC ss,0-12hr using a genotype-based dosing approach between black and white transplant recipients to incorporate precision medicine into immunosuppression. Development of a Bayesian estimator based on this population pharmacokinetics model with targeted CYP3A5 genotypes could provide an efficient and feasible predictive tool for clinicians to facilitate personalized dosing of tacrolimus.
